Dexcom Inc (NASDAQ:DXCM)’s traded shares stood at 2.81 million during the latest session, with the company’s beta value hitting 1.42. At the last check today, the stock’s price was $80.00, to imply an increase of 13.86% or $9.74 in intraday trading. The DXCM share’s 52-week high remains $132.26, putting it -65.32% down since that peak but still an impressive 28.1% since price per share fell to its 52-week low of $57.52. The company has a valuation of $31.37B, with an average of 3.8 million shares in intraday trading volume over the past 10 days and average of 4.31 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Dexcom Inc (DXCM), translating to a mean rating of 1.48. Of 12 analyst(s) looking at the stock, 0 analyst(s) give DXCM a Sell rating. 1 of those analysts rate the stock as Overweight while 1 advise Hold as 10 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.46.
Dexcom Inc (NASDAQ:DXCM) trade information
After registering a 13.86% upside in the latest session, Dexcom Inc (DXCM) has traded red over the past five days. The 5-day price performance for the stock is 11.64%, and 17.41% over 30 days. With these gigs, the year-to-date price performance is 2.87%. Short interest in Dexcom Inc (NASDAQ:DXCM) saw shorts transact 10.61 million shares and set a 2.22 days time to cover.
The extremes give us $28.125 and $146 for target low and target high price respectively. As such, DXCM has been trading -82.5% off suggested target high and 64.84% from its likely low.
Dexcom Inc (DXCM) estimates and forecasts
The rating firms project that company’s revenue will grow 14.24% compared to the previous financial year.
Revenue forecast for the current quarter as set by 20 analysts is 1.12B. Meanwhile, for the current quarter, a total of 20 analyst(s) estimate revenue growth to 1.17B.Earnings reports from the last fiscal year show that sales brought in 1B and 994.2M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 11.99% before jumping 17.89% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 39.06% for the past 5-year period. While 2025 is set for a 23.28% return in earnings, projections for the next 5 years are at 23.60% annually.
DXCM Dividends
Dexcom Inc has its next earnings report out on 2025-Apr-30. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Dexcom Inc (NASDAQ:DXCM)’s Major holders
Dexcom Inc insiders hold 0.41% of total outstanding shares, with institutional holders owning 96.31% of the shares at 96.70% float percentage. In total, 96.31% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 46.51 million shares (or 11.6516% of shares), all amounting to roughly $5.27 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 34.52 million shares, or about 8.6471% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.91 billion.
We also have VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Dexcom Inc (DXCM) shares. Going by data provided on Dec 31, 2024 , VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund holds roughly 12.26 shares. This is just over 3.13% of the total shares, with a market valuation of $984.38 million. Data from the same date shows that the other fund manager holds a little less at 10.57, or 2.70% of the shares, all valued at about 848.97 million.
